Skip to content
E1 · Randomised trialTrialPEM unclearPeer-reviewed
Standard · 3 min

Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment.

Young, Joel L, Powell, Richard N, Powell, Anna et al.

Journal of psychopharmacology (Oxford, England)2025DOIPubMed

Design
Randomised trial
Participants
Not reported
PEM required
Unclear
Case definition
Not stated in the abstract

Quick Summary

Researchers tested whether a medication called solriamfetol could help reduce fatigue in people with ME/CFS. In this 8-week study, some patients received the medication (starting at 75mg and potentially increasing to 150mg) while others received a placebo. By week 8, patients taking solriamfetol reported significantly less severe fatigue compared to those on placebo, and they also showed improvements in thinking and memory abilities. The medication was generally well tolerated, though some people experienced sleep problems and headaches.

Why It Matters

This is the first controlled trial demonstrating that solriamfetol may effectively reduce fatigue severity in ME/CFS patients, addressing a condition with no FDA-approved treatments. The findings are significant because they suggest a dual norepinephrine-dopamine mechanism may help address both fatigue and cognitive symptoms—two core debilitating features of ME/CFS. This study opens a potential new therapeutic avenue and provides evidence for larger-scale clinical trials.

Observed Findings

What the study reports it measured.

  • Solriamfetol significantly improved Fatigue Symptom Inventory severity scores compared to placebo at week 8 (p=0.039), but not at week 6 (p=0.270).
  • Solriamfetol improved executive function on the BRIEF-A global composite at week 8 (p=0.012), driven by improvements in metacognition (p=0.004).
  • Behavioral regulation index scores showed no significant difference between solriamfetol and placebo (p=0.574).
  • The most common adverse events were sleep loss and headaches, with the medication demonstrating overall good tolerability.
  • Improvement in fatigue severity appeared to require the full 8-week treatment period.

Inferred Conclusions

What the authors interpret from those results.

  • Solriamfetol has potential as a treatment for fatigue symptoms in ME/CFS patients, likely through dual norepinephrine-dopamine reuptake inhibition and wakefulness-promoting mechanisms.
  • The medication may address not only fatigue but also cognitive dysfunction, specifically higher-order thinking and planning abilities.
  • Solriamfetol demonstrates an acceptable safety profile in this patient population, warranting further investigation in larger trials.

Remaining Questions

  • What is the optimal dosing regimen and duration of treatment for maximum benefit in ME/CFS patients?
  • Does solriamfetol benefit persist beyond 8 weeks, and are there long-term safety concerns with extended use?
  • Which ME/CFS patient subgroups are most likely to respond to solriamfetol—does baseline symptom severity, genetic factors, or disease phenotype predict response?
  • How does solriamfetol's mechanism compare to other potential treatments, and can it be combined with other therapies?

What This Study Does Not Prove

This small 8-week study does not establish long-term safety or efficacy beyond 8 weeks, nor does it prove solriamfetol is effective for all ME/CFS patients or at all disease severity levels. The study cannot determine whether improvements result from direct disease modification or symptom management alone. Generalizability is limited by the small sample size and specific patient population enrolled; results may not apply to all ME/CFS presentations.

Explore further

About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →

Cite this study

The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.

Primary citation

Young, Joel L, Powell, Richard N, Powell, Anna, Welling, Lisa L M, Granata, Lauren, & Saal, Jaime (2025). Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment.. Journal of psychopharmacology (Oxford, England). https://doi.org/10.1177/02698811251368371

BibTeX

@article{mecfsatlas-young-2025-solriamfetol-improves,
  author  = {Young, Joel L and Powell, Richard N and Powell, Anna and Welling, Lisa L M and Granata, Lauren and Saal, Jaime},
  title   = {Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment.},
  journal = {Journal of psychopharmacology (Oxford, England)},
  year    = {2025},
  doi     = {10.1177/02698811251368371},
  note    = {PubMed: 40958377},
  url     = {https://www.mecfsatlas.com/evidence/young-2025-solriamfetol-improves},
}

Atlas snapshot reference

ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-11-14. https://www.mecfsatlas.com/evidence/young-2025-solriamfetol-improves

Contribute

Private, reviewed by a human. Not a public comment thread.